40550-12-7

Upstream product

• 5966-51-8 1,3-bis-(dimethylamino)propan-2-ol 

Downstream Products

• 113183-81-6 N²-(4-methoxy-benzyl)-N¹,N¹,N³,N³-tetramethyl-N²-phenyl-propane-1,2,3-triyltriamine 
• 122984-57-0 hydrochloric acid salt of 1,3-bis(dimethylamino)-2-propyl-4-chlorophenoxyacetate 
• 96111-17-0 1-(4-butoxy-phenoxy)-2,3-bis-dimethylamino-propane 
• 25827-24-1 C₁₉H₂₇N₃OS 
• 58-37-7 Proquamezin 
• 102322-18-9 tetra-N-methyl-2-phenothiazin-10-yl-propanediyldiamine 

Relevant academic research and scientific papers

Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II

A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C1-C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1-C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R10, CON(R12)2, OCON(R12), SR10, SOR11, SO2(R11), SO2N(R12)2, N(R12)2, NR10SO2R11, N(SO2R11)2NR10(CH2)nCN, NR10COR11, OCOR11 or COR10; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C1-C6 alkoxy, C1-C6 alkyl, SR10 and N(R12)2; Q is C1-C6 alkylene which is unsubstituted or substituted by (i) C1-C6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not, to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R12); R1 and R9, which are the same or different, are each hydrogen or C1-C6 alkyl, or R8 and R9 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R8 and R9 is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; or a pharmaceutically acceptable salt thereof; with the proviso that at least one R1 to R4 is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.

Cationic polysaccharides and reagents for their preparation

Cationic polysaccharide derivatives are prepared by reacting a polysaccharide with a polycationic reagent having one polysaccharide reactive group and at least two cationic groups. Suitable reagents include polycationic alkyl, aryl, alkaryl, cycloaliphatic, or heterocyclic amines, some of which are novel compositions. The polycationic polysaccharide derivatives prepared from these reagents are useful in the manufacture of paper.